Inclusion Criteria:  Written informed consent Aged 18 or above Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Documented PD-L1 expression by PD-L1 IHC per local report. Confirmed progression during treatment with a CPI-including regimen. ECOG performance status of 0 or 1 at enrolment. Life expectancy of ≥ 12 weeks at enrolment. Adequate bone marrow, liver and kidney function  Exclusion Criteria:  Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation) Previous treatment with an anti-TIGIT therapy Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment. Primary or secondary resistance after treatment with 2 or more regimens including a CPI. Symptomatic central nervous system (CNS) metastasis. Thromboembolic event within 3 months prior to enrolment. Other invasive malignancy within 2 years prior to screening.